Site search

Clear filter
2811 results for '' found
The role of CT Angiography as a suitable alternative to Invasive Coronary Angiography in detecting Left Main Restenosis (Trial Not Registered)
The role of CT Angiography as a suitable alternative to Invasive Coronary Angiography in detecting Left Main Restenosis (Trial Not Registered)
/
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous inj
/
An Open label study to evaluate the long term safety and efficacy of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema (NCT04739059)
An Open label study to evaluate the long term safety and efficacy of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema (NCT04739059)
/
Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 [Etranacogene Dezaparvovec] Gene Therapy Administered to Adult Subjects with Severe or Moderately
Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 [Etranacogene Dezaparvovec] Gene Therapy Administered to Adult Subjects with Severe or Moderately
/
A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1116 (4-Factor Prothrombin Complex Concentrate [Kcentra® / Beriplex® ]) to Imp
A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1116 (4-Factor Prothrombin Complex Concentrate [Kcentra® / Beriplex® ]) to Imp
/
A Double-Blind, Placebo-Controlled, Proof-of-Concept Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod on Recovery after Ischemic Stroke (NCT06987643)
A Double-Blind, Placebo-Controlled, Proof-of-Concept Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod on Recovery after Ischemic Stroke (NCT06987643)
/
A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a tri-specific antibody targeting PD-1/VEGFA/CTLA-4,
A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a tri-specific antibody targeting PD-1/VEGFA/CTLA-4,
/
A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9–Engineered T Cells (CTX112) in Subjects With Relaps
A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9–Engineered T Cells (CTX112) in Subjects With Relaps
/
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) (NCT05583227)
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) (NCT05583227)
/
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (Also Known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients With Unre
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (Also Known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients With Unre
/
41 42 43 44 45